Table of Contents Author Guidelines Submit a Manuscript
Obstetrics and Gynecology International
Volume 2014, Article ID 536896, 4 pages
http://dx.doi.org/10.1155/2014/536896
Research Article

Does Polycystic Ovary Syndrome Itself Have Additional Effect on Apelin Levels?

1Department of Obstetrics and Gynecology, Faculty of Medicine, Mustafa Kemal University, Antakya, Hatay, Turkey
2Department of Internal Medicine, Faculty of Medicine, Mustafa Kemal University, Antakya, Hatay, Turkey
3Department of Family Medicine, Faculty of Medicine, Mustafa Kemal University, Antakya, Hatay, Turkey
4Department of Public Health, Faculty of Medicine, Mustafa Kemal University, Antakya, Hatay, Turkey

Received 4 July 2014; Accepted 18 September 2014; Published 7 October 2014

Academic Editor: Curt W. Burger

Copyright © 2014 Dilek Benk Silfeler et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Kaya, S. D. Cengiz, B. Berker, S. Demirtaş, M. Cesur, and G. Erdoğan, “Comparative effects of atorvastatin and simvastatin on the plasma total homocysteine levels in women with polycystic ovary syndrome: a prospective randomized study,” Fertility and Sterility, vol. 92, no. 2, pp. 635–642, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Ovalle and R. Azziz, “Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus,” Fertility and Sterility, vol. 77, no. 6, pp. 1095–1105, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. D. A. Ehrmann, D. R. Liljenquist, K. Kasza, R. Azziz, R. S. Legro, and M. N. Ghazzi, “Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome,” The Journal of Clinical Endocrinology and Metabolism, vol. 91, pp. 41–53, 2006. View at Google Scholar
  4. Y. Sahin, K. Unluhizarci, A. Yilmazsoy, A. Yikilmaz, E. Aygen, and F. Kelestimur, “The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome,” Clinical Endocrinology, vol. 67, no. 6, pp. 904–908, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Carmina, M. C. Chu, R. A. Longo, G. B. Rini, and R. A. Lobo, “Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 5, pp. 2545–2549, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. C. E. Pepene, “Evidence for visfatin as an independent predictor of endothelial dysfunction in polycystic ovary syndrome,” Clinical Endocrinology, vol. 76, no. 1, pp. 119–125, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. C.-Y. Chang, Y.-C. Tsai, C.-H. Lee, T.-F. Chan, S.-H. Wang, and J.-H. Su, “Lower serum apelin levels in women with polycystic ovary syndrome,” Fertility and Sterility, vol. 95, no. 8, pp. 2520.e2–2523.e2, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Boucher, B. Masri, D. Daviaud et al., “Apelin, a newly identified adipokine up-regulated by insulin and obesity,” Endocrinology, vol. 146, no. 4, pp. 1764–1771, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. M. V. Heinonen, A. K. Purhonen, P. Miettinen et al., “Apelin, orexin-A and leptin plasma levels in morbid obesity and effect of gastric banding,” Regulatory Peptides, vol. 130, no. 1-2, pp. 7–13, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Li, G. Yang, Q. Li et al., “Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects,” Experimental and Clinical Endocrinology & Diabetes, vol. 114, no. 10, pp. 544–548, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Erdem, T. Dogru, I. Tasci, A. Sonmez, and S. Tapan, “Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus,” Experimental and Clinical Endocrinology and Diabetes, vol. 116, no. 5, pp. 289–292, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. J. P. Goetze, J. F. Rehfeld, J. Carlsen et al., “Apelin: a new plasma marker of cardiopulmonary disease,” Regulatory Peptides, vol. 133, no. 1–3, pp. 134–138, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. I. Tasci, T. Dogru, I. Naharci et al., “Plasma apelin is lower in patients with elevated LDL-cholesterol,” Experimental and Clinical Endocrinology and Diabetes, vol. 115, no. 7, pp. 428–432, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, “Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome,” Fertility and Sterility, vol. 81, pp. 19–25, 2004. View at Google Scholar
  15. R. Hatch, R. L. Rosenfield, M. H. Kim, and D. Tredway, “Hirsutism: implications, etiology, and management,” American Journal of Obstetrics & Gynecology, vol. 140, no. 7, pp. 811–830, 1981. View at Google Scholar · View at Scopus
  16. L. F. Orsini, S. Salardi, G. Pilu, L. Bovicelli, and E. Cacciari, “Pelvic organs in premenarcheal girls: real-time ultrasonography,” Radiology, vol. 153, no. 1, pp. 113–116, 1984. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Cekmez, Y. Cekmez, Ö. Pirgon et al., “Evaluation of new adipocytokines and insulin resistance in adolescents with polycystic ovary syndrome,” European Cytokine Network, vol. 22, no. 1, pp. 32–37, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Olszanecka-Glinianowicz, P. Madej, M. Nylec et al., “Circulating apelin level in relation to nutritional status in polycystic ovary syndrome and its association with metabolic and hormonal disturbances,” Clinical Endocrinology, vol. 79, no. 2, pp. 238–242, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. S. Choi, H. I. Yang, S. Cho et al., “Serum asymmetric dimethylarginine, apelin, and tumor necrosis factor-α levels in non-obese women with polycystic ovary syndrome,” Steroids, vol. 77, no. 13, pp. 1352–1358, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. A. D. Medhurst, C. A. Jennings, M. J. Robbins et al., “Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin,” Journal of Neurochemistry, vol. 84, no. 5, pp. 1162–1172, 2003. View at Publisher · View at Google Scholar · View at Scopus